Trial Profile
A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sapanisertib (Primary)
- Indications Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2021 Results assessing the safety and tolerability of sapanisertib in combination with carboplatin plus paclitaxel in patients with advanced solid malignancies enriched with mTOR pathway alterations presented at the 112th Annual Meeting of the American Association for Cancer Research